Lilly separates a neuroscience research group

With momentum building in its Alzheimer’s disease research, Eli Lilly and Company says it will split its Lilly Bio-Medicines division into neuroscience and immunology groups. The neuroscience unit will be responsible for pain and neurodegeneration drugs that have been launched or are in Phase 3 trials, including the potential Alzheimer’s treatment donanemab. In immunology, Lilly recently announced positive Phase 3 trials for mirikizumab for ulcerative colitis and lebrikizumab for atopic dermatitis. Lilly also announced the merger of Loxo Oncology, which it acquired in 2019, with its oncology unit.